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Putting Together the Pieces: Recent Proposals
To Fill in the Genetic Testing Regulatory
Puzzle
SerraJ. Schlanger*
Molecular genetic research has expanded rapidly since the first
description of DNA's double helix structure was published in 1953.1 The
modern "Genomic Era" began in 2003 when the Human Genome Project
announced the completed sequencing of the human genome. Since the
completion of the Human Genome Project, advances in genetic testing have
increased dramatically.3 Although there are currently genetic tests available
for over 2,000 diseases,4 less than ten percent of the tests available for
clinical use have been reviewed for clinical validity and utility.5
Furthermore, the United States Food and Drug Administration (FDA) has
approved less than a dozen of the commercially available genetic tests.6
The substantial proliferation of genetic testing has led to many debates
about the safety and appropriate use of this technology.' Discussion
regarding the necessary and appropriate amount of regulation for genetic
testing has continued for over fifteen years.8 Despite this prolonged
J.D., 2011, University of Maryland School of Law (Baltimore,
MD); B.A., 2005, Science,
Technology, and Society, Vassar College (Poughkeepsie, NY). The author currently
practices health law in Washington, D.C. and wishes to thank Professor Lawrence Sung at
the University of Maryland School of Law for his comments.
1. Alan E. Guttmacher & Francis S. Collins, Welcome to the Genomic Era, 349 NEW
ENG. J. MED. 996, 996 (2003); see generally James D. Watson & Francis H.C. Crick, A
Structurefor Deoxyribose Nucleic Acid, 171 NATURE 737 (1953). ) (theorizing on DNA's
double helix structure).
2. Guttmacher & Collins, supra note 1, at 996.
3. See generally GeneTests: Growth of Laboratory Directory, NAT'L CTR. FOR
BIOTECHNOLOGY INFO., http://www.ncbi.nlm.nih.gov/projects/GeneTests/static/whatsnew
/labdirgrowth.shtml. (last visited Sept. 29, 2011) (charting the increasing number of diseases
for which genetic testing is available).
4. Id.
5. Amy L. McGuire et al., Regulating Direct-to-ConsumerPersonal Genome Testing,
330 SCIENCE 181, 181 (2010).
6. Joan L. McGregor, Why John Stuart Mill Would Support Restriction on DTC
Marketing of Genetic Tests, 8 AM. J. BIOETHICS 9, 9 (2008).
7. Stuart Hogarth et al., Closing the Gaps-Enhancing the Regulation of Genetic Tests
Using Responsive Regulation, 62 FOOD & DRUG L.J. 831, 831 (2007).
8. Stuart Hogarth, Myths, Misconceptions and Myopia: Searching for Clarity in the
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discussion, "no new issues are [currently] on the table."' The debate about
genetic test regulation continues to focus on concerns regarding the
predictive quality and proper interpretation of genetic test results, the
potential misuse of genetic information, the appropriate uses of direct-toconsumer (DTC) genetic test marketing, and the ability to distinguish
clinically-valid tests from flawed pseudoscience.10
Many of the concerns about genetic testing may be traced to the special
nature of genetic information and the fact that genetic testing differs from
other diagnostic tests and medical treatments." The debate about the
necessary and appropriate regulation of genetic testing may be based on the
perception that genetic information is more central to our individuality than
other biological and medical information. 12 Genetic information is unique
to the individual, but is also inherently familial because the test results can
reveal information about that individual's genetic relatives.13 Genetic
testing differs from other medical tests because the tests may be used to
determine the probability of disease development and to identify risks in
individuals without symptoms. 14 Such predictive genetic tests may provide
information about diseases, conditions, and disorders for which there are no
available treatments or preventive measures" Furthermore, even with a
positive genetic test result, the probability that an individual will develop
the disease, condition, or disorder is uncertain.16 A negative test result
merely indicates the absence of a particular gene sequence that is associated
with a particular condition and does not completely rule out the possibility
Debate about the Regulation of Consumer Genetics, 13 PUB. HEALTH GENOMICS 322, 324
(2010).
9. Id.
10. See Guttmacher & Collins, supra note 1, at 997-98 (outlining the concerns already
evident at the beginning of the genomic era).
11. Gail H. Javitt, Erica Stanley & Kathy Hudson, Direct-to-Consumer Genetic Tests,
Government Oversight, and the First Amendment: What the Government Can (and Can't)
Do to Protect the Public's Health, 57 OKLA. L. REV. 251, 260 (2004).
12. Michael J. Green & Jeffrey R. Botkin, "Genetic Exceptionalism" in Medicine:
Clarifying the Differences between Genetic and Nongenetic Tests, 138 ANNALS INTERNAL
MED. 571, 572 (2003).
13. Patricia Roche, Caveat Venditor: Protecting Privacy and Ownership Interests in
DNA, HUMAN DNA: LAW AND POLICY INTERNATIONAL AND COMPARATIVE PERSPECTIVES 33,
34 (Bartha M. Knoppers ed., 1997).
14. Green & Botkin, supranote 12, at 571.
15.
SEC'Y's ADVISORY COMM. ON GENETICS, HEALTH, AND Soc'Y, U.S. DEP'T OF
HEALTH & HUMAN SERVS., U.S. SYSTEM OF OVERSIGHT OF GENETIC TESTING: A RESPONSE TO
THE CHARGE OF THE SECRETARY OF HEALTH AND HUMAN SERVICES 18 (April 2008),

availableat http://oba.od.nih.gov/oba
/SACGHS/reports/SACGHS oversight report.pdf.
16. PROMOTING SAFE AND EFFECTIVE GENETIC

TESTING IN THE UNITED STATES: FINAL
REPORT OF THE TASK FORCE ON GENETIC TESTING 3 (Neil A. Holtzman & Michael S. Watson

eds., 1998) [hereinafter FINAL REPORT], available at http://www.genome.gov/10001733.
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of future disease development." Similarly, a positive test result merely
indicates the presence of a particular gene sequence; a positive result does
not mean that the individual will definitely develop that particular disease.
Even if the presence of a particular genetic sequence is directly correlated to
the future development of a particular condition, the positive test result does
not indicate when the condition will develop or the severity of the
condition. 19 Complex interactions between an individual's genes and
environmental factors influence and determine if and how a condition
develops. 20
Recent developments in health care reform and new proposals by genetic
testing companies have once again sparked the debate about the regulation
of genetic testing. Two distinct approaches have been proposed by two
different agencies within the Department of Health and Human Services
(DHHS) to address some of the concerns about the accuracy, validity, and
ability of this technology. Part I of this article will discuss the current
federal regulatory framework for genetic testing and genetic information.21
Part II will explore the recent developments that have prompted the
agencies to propose changes to the current regulatory framework.22 Part III
will address some of the concerns and challenges facing the implementation
23
of these proposed changes.
Finally, Part IV will evaluate the two
proposals and the competing interests in order to suggest how genetic
testing may best be regulated to meet the needs of the industry, clinicians,
researchers, patients, and consumers.24
I. THE CURRENT FEDERAL REGULATORY FRAMEWORK
Genetic testing is currently covered by three different regulatory
schemes. The FDA, under the Federal Food, Drug, and Cosmetic Act
(FDCA), may regulate genetic tests as medical devices.25 The Clinical
Laboratory Improvement Amendments of 1988 (CLIA) give the Centers for
Medicare and Medicaid Services (CMS) the authority to ensure the validity
and reliability of clinical laboratory testing.26 The Genetic Information
Nondiscrimination Act of 2008 (GINA) protects the use and dissemination

17.
18.
19.
20.
21.
22.
23.
24.
25.
26.

Id.
Id.
Javitt, Stanley & Hudson, supra note 11, at 260-61.
Guttmacher & Collins, supra note 1, at 997.
See infra Part I.
See infra Part II.
See infra Part III.
See infra Part IV.
21 U.S.C. §§ 301-399 (2006).
42 U.S.C. § 263a (2006).
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of genetic information.27
A. Medical Device Regulation

The FDCA 2 8 and the Medical Device Amendments of 197629 give
authority to the FDA to regulate medical devices. 3 0 A medical device is
defined as "an instrument, apparatus, implement, machine, contrivance,
implant, in vitro reagent, or other similar or related article, including any
component, part, or accessory, which is ... intended for use in the
diagnosis of disease or other conditions, or in the cure, mitigation,
treatment, or prevention of disease[.]" 3
The FDA uses three categories of medical devices to determine how
much review is necessary to ensure the safety and effective use of each
device. 32 Class I devices are subject to the least FDA regulation oversight
and may be introduced directly into U.S. commerce.33 Class II devices have
an increased safety risk and are subject to greater FDA controls including
post-marketing surveillance and device performance standards to ensure
safety and effectiveness.34 Class III devices are defined as those: 1) for
which insufficient information exists to determine a reasonable assurance of
safety and effectiveness through general or special controls; and 2) which
are either for (a) supporting, sustaining, or preventing impairment of human
health, or (b) present a potential unreasonable risk of illness of injury.
This final class is subject to the greatest FDA oversight.36
Although the definition of a medical device provides the FDA broad
authority to regulate genetic tests, the FDA has previously chosen to limit
its regulation of genetic tests.37 This limited regulation of genetic tests may
be attributed to the FDA regulatory distinction between genetic "home
brew" or "laboratory developed" tests (LDTs), which are developed and
analyzed completely within one laboratory, and genetic tests that contain
27. Genetic Information Nondiscrimination Act, Pub. L. No. 110-233, 122 Stat. 881
(2008) (to be codified in scattered sections of 26, 29 & 42 U.S.C.).
28. 21 U.S.C. §§ 301-399 (2006).
29. Pub. L. No. 94-295, 90 Stat. 539 (1976) (codified in scattered sections of21 U.S.C.).
30. 21 U.S.C. § 321(h) (2006).
31. Id.
32. Neil A. Holtzman, FDA and the Regulation of Genetic Tests, 41 JURIMETRICS 53, 59
(2000).
33. 21 U.S.C. § 360c(a)(1)(A) (2006).
34. 21 U.S.C. § 360c(a)(1)(B).
35. 21 U.S.C. § 360c(a)(1)(C).
36. Id.
37. See Andrew S. Robertson, Taking Responsibility: Regulations and Protections in
Direct-to-Consumer Genetic Testing, 24 BERKELEY TECH. L.J. 213, 223-24 (2009)
(explaining that the FDA has exercised "enforcement discretion" in the regulation of certain
genetic tests).
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components that travel in interstate commerce.38 The FDA has previously
chosen to regulate only the individual components and reagents used in
genetic tests and has declined to regulate the LDTs or the laboratories that
develop and analyze them.39 Consequently, these LDTs are classified as
Class I or II medical devices that are subject to less regulation than other
genetic tests. 4.0 Practically, this allows certain genetic tests to reach the
consumer market without any FDA evaluation for safety, effectiveness, or
accuracy. 41 Consumers who purchase these DTC genetic tests "are likely
unaware that the FDA is not involved in [any] quality manufacturing
control or efficacy testing" of the products.42
In addition to these self-imposed regulatory distinctions, the FDA has
previously stated that its regulatory power over medical devices cannot be
extended to regulate genetic tests marketed as services.
This allows
companies that market their LDTs as services to circumvent the entire FDA
44
pre-market approval process.
The limited regulation of genetic tests may also be due to the availability
of the FDA's pre-market notification process.45 The pre-market notification
process, also known as 510(k) abbreviated marketing clearance, requires
that developers "demonstrate that their new test is substantially equivalent
to a medical device currently on the market."46 If the genetic test developer
can produce data that demonstrates that a new test is substantially
equivalent to a test already available on the market, the new test can be
marketed in the same class as that test, and the developer does not need to
prove the new test's safety and effectiveness in order to gain pre-market
approval.47
In addition to the market approval regulations, the FDA has regulations
38. Rebecca Antar Novick, Note, One Step at a Time: EthicalBarriersto Home Genetic
Testing and Why the U.S. Health Care System is Not Ready, 11 N.Y.U. J. LEGIS. & PUB.
POL'Y 621, 629 (2008).
39. Bruce Patsner, New "Home Brew" Predictive Genetic Tests Present Significant
Regulatory Problems,9 Hous. J. HEALTH L. & POL'Y 237, 251-52 (2009). See also Medical
Devices; Classification/Reclassification; Restricted Devices; Analyte Specific Reagents, 62
Fed. Reg. 62,243, 62,245 (Nov. 21, 1997) (codified at 20 C.F.R. §§ 809, 864) (discussing the
FDA's intention not to regulate the reagents used in genetic tests differently from other Class
I medical devices).
40. Patsner, supra note 39, at 249.
41. Id. at 254.
42. Id. at 249-50.
43. Holtzman, supra note 32, at 61.
44. Patsner, supra note 39, at 254.
45. See Lauren Solberg, Note, Over the Counter but Under the Radar: Direct-toConsumer Genetics Tests and FDA Regulation of Medical Devices, 11 VAND. J. ENT. &
TECH. L. 711, 730 (2009) (introducing the pre-market notification process).
46. Id.
47. Holtzman, supra note 32, at 60.
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regarding medical device labeling that may be applied to genetic tests. 4 8
Genetic tests that include FDA regulated components must comply with the
promulgated regulations regarding general medical device labeling,49 as
well as with regulations for in vitro diagnostic products.50 Pursuant to this
authority, the FDA requires that the advertising and promotional materials
for some genetic tests "state that their '[a]nalytic and performance
characteristics are not established' . . . because they are 'not clinically
Result reports generated from these tests are also required to
validated."'
52
include a notification that the test is not cleared or approved by the FDA.
However, these provisions have not been uniformly enforced. Furthermore,
genetic tests that are classified as Class I or II medical devices are not
considered restricted medical devices, and thus are not subject to the
additional advertising regulations.5 ' DTC genetic tests and LDT kits are
generally not subject to these regulations, so the labels and materials
included with these tests may include information that has not been
substantiated. 54
B. Clinical LaboratoryRegulation
CMS has authority to regulate medical testing within clinical laboratories
under CLIA.55 CLIA establishes regulations to ensure that every laboratory
determines the analytical validity of its laboratory tests before offering them
for clinical purposes, such as use for disease diagnosis, prevention, or
Although CLIA was enacted to certify valid and reliable
treatment.
medical testing, it does not authorize or certify the validity of the individual

48. Solberg, supra note 45, at 728-29.
49. 21 C.F.R. § 801.1 (2010).
50. 21 C.F.R. § 809.10 (2010).
51. Jennifer E. Spreng, The Food and Drug Administration and the Pharmacy
Profession:Partnersto Ensure the Safety and Efficacy of the PharmacogenomicTherapy, 13
J.HEALTH CARE L. & POL'Y 77, 91-92 (2010).
52. Id.
53. See Marketing or Medicine: Are Direct-to-ConsumerDevice Ads Playing Doctor?:
Hearing Before the S. Special Comm. on Aging, 110th Cong. 67 (2008) (statement of Daniel
Schultz, Dir., Ctr. for Devices and Radiological Health, Food & Drug Administration),
available at http://www.fda.gov/NewsEvents/Testimony/ucm096272.htm (explaining that
"few Class I and Class II devices are restricted by regulation").
54. Solberg, supra note 45, at 729.
55. 42 U.S.C. § 263a (2006); see also Clinical Laboratory Improvement Amendments
(CLIA) Overview, CTRS. FOR MEDICARE & MEDICAID SERVS., http://www.cms.gov/CLIA/
(last visited Oct. 1, 2011).
56. BIN CHEN ET AL., CTRS. FOR DISEASE CONTROL & PREVENTION, 58 MORBIDITY AND
MORTALITY WEEKLY REPORT: GOOD LABORATORY PRACTICES FOR MOLECULAR GENETIC
TESTING FOR HERITABLE DISEASES AND CONDITIONS 3 (2009); Holtzman, supra note 32, at

57.
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tests. 57
CLIA imposes basic requirements for laboratory methodology and
documentation, as well as standards for personnel qualification, in order for
a laboratory to receive certification." CLIA certification requires periodic
facility inspections and the examination of proficiency sample tests for
high-complexity tests. 59 Although genetic tests are highly complex and
require precise skill to perform and interpret, CMS does not require
laboratories that perform genetic testing to undergo specific proficiency
examinations for the genetic tests. 60 Under CLIA, "there are no specified
quality control, personnel, or proficiency testing requirements mandated ...
for most genetic tests."6' Although laboratories that perform genetic tests
must meet some personnel requirements to fulfill the certification
requirements for high-complexity testing, the actual laboratories are only
subject to the general CLIA methodology and documentation
requirements. 62 Furthermore, CLIA "does not require [that] laboratories
address the clinical validity or utility of tests [performed]."63 This is
particularly problematic for "home brew" genetic tests because CLIA does
not include explicit authorization or a process for evaluating test accuracy.64
Although CLIA requires that clinical laboratories report any changes
regarding offered examinations, tests, and procedures to the Secretary of
DHHS,65 CLIA does not authorize CMS to limit or restrict the offering of a
particular test.66 The decision to offer new genetic tests is left to the
discretion of each individual laboratory.67
C. Genetic Information Regulation
Prior to the passage of GINA in May 2008, the protection of genetic
information in the United States was governed by an assortment of federal

57. Robertson, supra note 37, at 222.
58. 42 U.S.C. §§ 263a(d)(1), (e)(2)(D), (t)(1) (2006).
59. 42 U.S.C. §§ 263a(d)(3), (f)(3)(A); Gail H. Javitt & Kathy Hudson, Federal Neglect:
Regulation of Genetic Testing, 22 ISSUES IN SCi. & TECH. 59, 59 (2006), available at
http://www.dnapolicy.org/resources/Issues-inScience-andTechnology.pdf.
60. Javitt & Hudson, supra note 59, at 59-61.
61. At Home DNA Tests: Marketing Scam or Medical Breakthrough:HearingBefore the
S. Special Comm. on Aging, 109th Cong. 35-36 (2006) (statement of Kathy Hudson, Dir.,
Genetics & Pub. Policy Ctr., and Assoc. Professor, Berman Bioethics Inst., Inst. of Genetic
Med. and Dep't of Pediatrics, Johns Hopkins Univ.).
62. 42 C.F.R. §493.1495 (2010); see CHEN, supra note 56, at 3.
63. Holtzman, supra note 32, at 57.
64. Javitt & Hudson, supra note 59, at 61.
65. 42 U.S.C. § 263a(d)(2)(B) (2006).
66. Javitt & Hudson, supra note 59, at 61.
67. Id
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and state statutes and regulations.6 8 The states' earliest efforts began in the
1970s and were designed as anti-discrimination responses to specific
genetic conditions. 69 Following the establishment of the Human Genome
Project, many more states began to develop regulations and restrictions
governing the use of genetic information. Since each state created its own
policies, the laws varied widely in their approach, classification,
application, and level of protection.
Some states relied on privacy
grounds to justify the protection of genetic information, while other states
relied on property rights.71 State laws were separated into three categories
of protection: "(1) trait protection; (2) prohibition of discrimination from
the results of genetic testing; and (3) forbidding discrimination in regards to
genetic information., 72 The wide variety of approaches and protections led
to compliance complications for employers, healthcare providers, and
individuals.73
Prior to GINA, a number of federal statutes also governed the protection
of genetic information, including: Title VII of the Civil Rights Act of 1964;
the Rehabilitation Act of 1973; the Employee Retirement Income Security
Act of 1974; Title XVIII of the Social Security Act; the Americans with
Disabilities Act; the Family and Medical Leave Act; the Occupational
Safety and Health Act; the Public Health Service Act; Executive Order
13145;74 and the Health Insurance Portability and Accountability Act of
1996." In addition, provisions in the Fourth, Fifth, and Fourteenth
Amendments concerning unreasonable searches and due process were
interpreted to provide another basis for the preservation of genetic
information and privacy. 76 Despite the large number and wide variety of
federal statutes and Constitutional provisions that potentially applied to

68.

See Karen H. Rothenberg, Social Implications of Genetic Testing, 3 N. AM.
J. 133, 134 (1999) (discussing the evolution of genetic testing in the 1970s and
1980s); Daniel Schlein, New Frontiersfor Genetic Privacy Law: The Genetic Information
NondiscriminationAct of 2008, 19 GEO. MASON U. C.R. L.J. 311, 347 (2009).
69. Rothenberg, supra note 68, at 134; Schlein, supra note 68, at 347.
70. Schlein, supra note 68, at 347.
71. Morse Hyun-Myung Tan, Advancing Civil Rights, The Next Generation: The
Genetic Information NondiscriminationAct of 2008 and Beyond, 19 HEALTH MATRIX 63, 88
(2009).
72. Id at 89.
73. See id. at 92 (explaining that individuals and genetic information may easily cross
state lines, which "present[ed] challenges for both individuals seeking protection and
governments enforcing [the] provisions.").
74. Patricia Nemeth & Terry W. Bonnette, Genetic Discriminationin Employment, 88
MICH. B.J. 42, 44 (2009) ("Since February 10, 2000, federal employees have been protected
under Executive Order 13145 against discharge or other restrictions in their employment or
employment benefits on the basis of genetic information.").
75. Tan, supra note 71, at 93-94; Schlein, supra note 68, at 318.
76. Schlein, supranote 68, at 345.
ACTUARIAL
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protect genetic privacy, substantial loopholes and irregularities in the
regulations did not adequately protect against the possibility of genetic
privacy breaches. After many years of political debate, President George
W. Bush signed GINA on May 21, 2008.77
GINA prohibits discrimination on the basis of genetic information for
health insurance and employment purposes.7 8 Genetic information is
defined as information about an individual's genetic tests, the genetic tests
of family members of such individual, and the manifestation of a disease or
disorder in family members of such individual. 79 Genetic information does
not include information about the sex or age of an individual.
Title I of GINA prohibits group health plans from adjusting premium or
contribution amounts on the basis of genetic information. To protect
individuals from discrimination by group health insurance providers, the
insurance issuer may not:
request or require an individual or family member of such individual to
undergo a genetic test [. . . , may] not request, require, or purchase
genetic information for underwriting purposes [. . . , and may] not

request, require, or purchase genetic information with respect to any
individual prior to such individual's enrollment under the plan or
coverage in connection with such enrollment. 80
Violation of these prohibitions results in financial penalties unless the
insurer can demonstrate that reasonable diligence was used to avoid
noncompliance.8
Title II of GINA prohibits employers from using genetic information to
make decisions regarding hiring, firing, job placement and promotions in
addition to regulating how employers may acquire an employee's genetic
information. Title II makes it "an unlawful employment practice for an
employer to fail or refuse to hire, or to discharge, any employee, or
otherwise to discriminate against any employee with respect to the
compensation, terms, conditions, or privileges of employment of the
employee, because of genetic information."82 It is also unlawful "to limit,
segregate, classify ... .] or otherwise adversely affect the status of the
employee [. . .]" because of genetic information.83 Employers are also
77. Press Release, White House, President Bush Signs H.R. 493, the Genetic
Information Nondiscrimination Act of 2008 (May 21, 2008).
78. Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, 122 Stat.
881 (to be codified in scattered sections of 26, 29, and 42 U.S.C.).
79. § 101(d), 122 Stat. at 885.
80. § 101(b), 122 Stat. at 883-84.
81. § 101(e), 122 Stat. at 886-87.
82. § 202(a)(1), 122 Stat. at 907.
83. § 202(a)(2), 122 Stat. at 907.
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prohibited from requesting, requiring, or purchasing the genetic information
of an employee or family member of the employee, with six exceptions for
inadvertent discovery, company offered health services, and workplace
genetic monitoring.84
II. RECENT DEVELOPMENTS AND PROPOSED CHANGES

A. FDA and CongressionalActions
In May 2010, Pathway Genomics (Pathway) announced a plan to sell one
of its genetic tests directly to consumers at national retail pharmacies
throughout the United States. 85 In response, the FDA sent a letter to
Pathway stating that the home-use genetic testing kit was a medical device
as defined in the FDCA." The FDA informed Pathway that the agency had
not cleared or approved their test and asked the company to either provide
documentation of the clearance, or approval, or the basis for their
determination that the company was not required to obtain FDA clearance
for the device.87 Pathway's attempt to sell genetic tests in retail pharmacies
also prompted the House Committee on Energy and Commerce (House
Committee) to begin a broad investigation of DTC genomic companies.
The House Committee sent letters to three companies requesting
information about the conditions and diseases the companies test for,
guidance materials related to genetic counseling and physician
consultations, and documentation about test accuracy, processing policies,
and FDA compliance. 89 Although Pathway stated that their test fell within
84. § 202(b), 122 Stat. at 907-08; see also Schlein, supra note 68, at 357-59 (explaining
the distinctions between the six exceptions to GINA's "presumption of unlawfulness when
an employer asks, requires, or purchases genetic information of an employee or an
employee's family member.").
85. Rob Stein, Company Plans to Sell Genetic Testing Kit at Drugstores, WASH. POST,
May 11, 2010, http://www.washingtonpost.com/wp-dyn/content/article/2010/05/1 0/AR
2010051004904.html.
86. Letter from James Woods, Deputy Dir., Patient Safety and Product Quality, Office
of In Vitro Diagnostic Device Evaluations and Safety, Ctr. for Devices and Radiological
Health, to James Plante, Founder & CEO, Pathway Genomics Corp. (May. 10, 2010),
availableat http://www.fda.gov/downloads/MedicalDevices/ResourcesforYou/Industry/UC
M211875.pdf.
87. Id.
88. Turna Ray, As Congress Investigates DTC Genomics Market, Firms Vow
Cooperation,PHARMACOGENOMICs REP. (May 26, 2010), http://www.genomeweb.com/

dxpgx/congress-investigates-dtc-genomics-market-firms-vow-cooperation.
89. Letter from Henry A. Waxman, Chairman, H. Comm. on Energy and Commerce, et
al., to James Plante, Chief Exec. Officer, Pathway Genomics Corp. (May 19, 2010),
availableat http://democrats.energycommerce.house.gov/documents/20100519/Plante.
PathwayGenomics.2010.5.19.pdf; Letter from Henry A. Waxman, Chairman, H. Comm. on
Energy and Commerce, et al., to Vance Vanier, Pres. & CEO, Navigenics (May 19, 2010),
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the current regulatory guidelines, the FDA's letter and the House
Committee's investigation prompted the national retail pharmacies to halt
retail genetic test sales until the regulatory concerns were resolved. 90
In June 2010, less than one month after the FDA and House Committee
began their investigations, 23andMe, a DTC genetic test company,
determined that a number of customer samples were incorrectly
processed.91 This mix-up resulted in a number of customers receiving and
viewing genetic data and test results that were not their own.92 Following
this mix-up, the House Committee asked 23andMe for additional
information about the company's policies and communications related to
the collection, processing, and analysis of customer samples.93 The FDA
sent 23andMe and four other genetic testing companies letters, similar to
the letter Pathway received, stating that the companies' tests were medical
devices subject to regulation under the FDCA.94 However, in these letters,
the FDA specified that the companies' services were not considered LDTs
availableat http://democrats.energycommerce.house.gov/documents/20100519/Vanier.
Navigencis.2010.5.19.pdf; Letter from Henry A.Waxman, Chairman, H. Comm. on Energy
and Commerce, et al., to Anne Wojcicki, Pres., 23andMe, Inc. (May 19, 2010), availableat
http://democrats.energycommerce.house.gov/documents/20100519/Wojcicki.23and
ME.2010.5.19.pdf.
90. Ray, supranote 88.
91. 23andMe, Updatefrom 23andMe, THE SPITTOON (June 8,2010,2:56 PM), http://
spittoon23andme.com/2010/06/08/update-from-23andme/.
92. Tuma Ray, UPDATE: 23andMe Says LabCorp Incorrectly Processed 96 Samples,
Mixing Up Customer Data, PHARMACOGENOMICS REP. (June 9, 2010), http://www.genome
web.com/dxpgx/update-23andme-says-labcorp-incorrectly-processed-96-samples-mixingcustomer-dat.
93. Congress Seeks More Information on 23andMe Data Mix-up, GENOMEWEB DAILY
NEWS (June 14, 2010), http://www.genomeweb.com/dxpgx/congress-seeks-moreinformation
-23andme-data-mix.
94. Letter from Alberto Gutierrez, Office of In Vitro Diagnostic Device Evaluation and
Safety, Ctr. for Device and Radiological Health, to Earl M. Collier, Jr., CEO, deCODE
Genetics, (June 10, 2010), availableat http://www.fda.gov/downloads/MedicaiDevices/
ResourcesforYou/Industry/UCM215241.pdf; Letter from Alberto Gutierrez, Office of In
Vitro Diagnostic Device Evaluation and Safety, Ctr. for Device and Radiological Health, to
Jorge Conde, Co-Founder & CEO, Knome, Inc. (June 10, 2010), available at
http://www.fda.gov/downloads/MedicalDevices/ResourcesforYou/Industry/UCM215239.pdf
; Letter from Alberto Gutierrez, Office of In Vitro Diagnostic Device Evaluation and Safety,
Ctr. for Device and Radiological Health, to Jay T. Flatley, President & CEO, Illumina, Inc.
(June 10, 2010), availableat http://www.fda.gov/downloads/MedicalDevices/Resources
forYou/Industry/UCM215242.pdf; Letter from Alberto Gutierrez, Office of In Vitro
Diagnostic Device Evaluation and Safety, Ctr. for Device and Radiological Health, to Vance
Vanier, President & CEO, Navigenics (June 10, 2010), availableat http://www.fda.gov/
downloads/MedicalDevices/ResourcesforYou/Industry/UCM215243.pdf;
Letter
from
Alberto Gutierrez, Office of In Vitro Diagnostic Device Evaluation and Safety, Ctr. for
Device and Radiological Health, to Anne Wojcicki, President & Co-Founder, 23andMe, Inc.
(June 10, 2010), availableat http://www.fda.gov/downloads/MedicalDevices/Resourcesfor
You/Industry/UCM215240.pdf.
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because the tests were not developed by and used in a single laboratory.9 5
In July 2010, the FDA sent letters to fourteen additional companies that
manufacture and market genetic tests.96 As in the previous letters, the FDA
explained that the companies' genetic tests were improperly being marketed
without FDA clearance or approval.9 7
During the summer of 2010, the FDA also announced a public meeting
and requested comments regarding the oversight of LDTs.98 The FDA
reached out to "interested stakeholders regarding reasonable and effective
regulation of LDTs." 99 In the Federal Register notice, the FDA
acknowledged that the agency had previously "exercised enforcement
discretion and [had] not enforced applicable regulations with respect to
The agency explained that this limited regulation was
LDTs[.]"' 0
acceptable when the initial LDTs, simple pathology tests, were developed
and used by clinicians working in the laboratories that developed and
interpreted the patients' results.' 0 1 However, the FDA noted that today's
LDTs are increasingly complex, use components that are not individually
regulated by the FDA, and assess high-risk conditions and diseases, often in
a remote laboratory that is removed from the test development laboratory
and the patient care offices.102 To address growing concerns about the
corporate development of LDTs and the increased use of these tests in
clinical disease management, the FDA suggested that a "risk-based
application of oversight to LDTs is the appropriate approach" to
regulation.10 3 The FDA held a public meeting over two days in July 2010
95. Letter from Gutierrez to Conde, supra note 94; Letter from Gutierrez to Wojcicki,
supra note 94; Tuma Ray, FDA Warns DTC Genomics Firms that Genetic Tests are Not
LDTs, May Need Clearance or Approval, PHARMACOGENOMICS REP. (June 15, 2010),
http://www.genomeweb.com/dxpgx/fda-warns-dtc-genomics-firms-genetic-tests-are-notldts-may-need-clearance-or-ap (reporting on the letters sent to five genetic test companies).
96. See, e.g., Letter from James Woods, Deputy Dir., Patient Safety and Product
Quality, Office of In Vitro Diagnostic Device Evaluations and Safety, Ctr. for Devices and
Radiological Health, to Harry F. Hixson, Jr., Chairman & CEO, Sequenom, Inc. (July 19,
2010), availableat http://www.fda.gov/downloads/MedicalDevices/ProductsandMedical
Procedures/InVitroDiagnostics/UCM219595.pdf. Links to the other thirteen letters are
available at http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitro
Diagnostics/ucm219582.htm (last visited Oct. 23, 2011). Three additional companies that
market genetic tests received letters from the FDA in May 2011. FDA Warns More DTC
Genetics Firms, GENOMEWEB DAILY NEWS (May 17, 2011), http://www.genomeweb.com
/dxpgx/fda-wams-more-dtc-genetics-firms.
97. Letter from Woods to Hixson, Jr., supra note 96.
98. Oversight of Laboratory Developed Tests; Public Meeting; Request for Comments,
75 Fed. Reg. 34,463 (June 17, 2010).
99. Id
100. Id.
101. Id.
102. Id.
103. Id at 34,464.
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and addressed four topics: 1) patient considerations, 2) challenges facing
laboratories, 3) DTC marketing of genetic testing, and 4) education and
outreach. 104 At the beginning of the meeting, Dr. Jeffrey Shuren, the FDA's
Director of the Center for Devices and Radiological Health, stressed that
although the agency had formally decided to regulate LDTs, it had not yet
decided how the agency would exercise that authority.'os
In the same week as the FDA's public meeting, the House Committee
also held a hearing about the marketing and regulation of genetic tests and
the effects of these tests on public health.106 At the House Committee
hearing, the Government Accountability Office (GAO) disclosed an
undercover report stating that the services of four DTC genetic test
companies were deceptive, fraudulent, and nearly useless. 07 The GAO
purchased tests from four different companies in order to investigate the
companies' marketing practices, testing data, and customer support.'os This
investigation was conducted to reassess the claims made by DTC genetic
testing companies following a prior investigation into claims about
personalized nutrition and lifestyle recommendations made by four DTC
genetic testing companies in 2006.109 Following the first undercover
investigation, Gregory Kutz, the Managing Director of Forensic Audits and
Special Investigations for the GAO, testified before the Senate Special
Committee on Aging that the sampled genetic tests at best provided little or
no value to consumers, and at worst "could frighten a consumer into

104. Id; see also U.S. Dep't of Health & Human Servs., Food & Drug Admin., Public
Meeting on Oversight ofLaboratoryDeveloped Tests Before the Food & DrugAdmin., (July
19, 2010) [hereinafter Public Meeting 1], availableat http://www.regulations.gov/Search/Re
gs/home.html#documentDetail?R=0900006480b65834; U.S. Dep't of Health & Human
Servs., Food & Drug Admin., Public Meeting on Oversight of LaboratoryDeveloped Tests
(July 20, 2010), availableat http://www.regulations.gov/search/Regs/home.html#document
Detail?R=0900006480b6591.
105. Public Meeting I, supra note 104, at 6-7.
106. Memorandum from the Comm. on Energy & Commerce Staff to the Subcomm. on
Oversight & Investigations Members & Staff (July 20, 2010), available at
http://democrats.energycommerce.house.gov/documents/20100720/Briefing.Memo.oi.2010.
7.20.pdf.
107. Matt Jones, DTC Genetics Services Hit Hard on the Hill as FDA Mulls Options,
GENOMEWEB DAILY NEWS (July 23, 2010), http://www.genomeweb.com/dxpgx/dtcgenetics-services-hit-hard-hill-fda-mulls-options.
108. GAO's Stealth Report Attacks "Deceptive" DTC Genetics, GENOMEWEB DAILY
NEWS (July 22, 2010), http://www.genomeweb.com/dxpgx/gaos-stealth-report-attacksdeceptive-dtc-genetics.
109. U.S. GOv'T ACCOUNTABILITY OFFICE, GAO-10-847T, DIRECT-TO-CONSUMER
GENETIC TESTS: MISLEADING TEST RESULTS ARE FURTHER COMPLICATED BY DECEPTIVE
MARKETING AND OTHER QUESTIONABLE PRACTICES 1-2 (2010) [hereinafter MISLEADING
TEST RESULTS]; see also U.S. Gov'T ACCOUNTABILITY
OFFICE, GAO-06-977T,
NUTRIGENETIC TESTING: TESTS PURCHASED FROM FOUR WEB SITES MISLEAD CONSUMERS 2

(2006).
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thinking that they will develop cancer, osteoporosis, heart disease, or brain
aging.""o After investigating the claims of four new DTC genetic testing
companies, in July 2010 Mr. Kutz testified before the House Committee
that the new test results the GAO received were just as "misleading and of
little or no practical use to consumers.""' After informing the FDA,
National Institutes of Health (NIH), and Federal Trade Commission (FTC)
of the findings, the GAO referred all of the companies investigated to the
FDA and FTC for appropriate action related to their claims.1 12
Even though discussions about the need for improved regulation of LDTs
and DTC genetic tests began in the spring of 2010, as of September 2011
the FDA was still in the drafting phase and had issued limited guidance
about how the regulations will develop." 3 This may be related to the large
number of public submissions that the FDA received in response to the
notice for public comment and at the public meetings."14 The House
Committee has also not taken any significant action since the hearings in
July 2010. One of the greatest steps towards improved regulation occurred
in June 2010, when CMS and the FDA signed a Memorandum of
Understanding (MOU) that acknowledged the need for greater collaboration
between the two agencies."' The agencies "agree[d] to work together to
promote initiatives related to the review and use of FDA-regulated. . .
medical devices[.]"ll 6 Throughout the discussions of increased FDA
regulation, the FDA has mentioned using a test registry to monitor available
genetic tests.

110. At Home DNA Tests: Marketing Scam or Medical Breakthrough: HearingBefore
the S. Special Comm. on Aging, 109th Cong. 3-4 (2006) (statement of Gregory Kutz,
Managing Director of Forensic Audits and Special Investigations, United States Government
Accountability Office).
111. MISLEADING TEST RESULTS, supra note 109, at 4.
112. Id. at 19.
113. Molika Ashford, At Dx Conference, FDA's Gutierrez Sheds FurtherLight on Plans
for Risk-Based LDT Regulation, PHARMACOGENOMICS REP. (Sept. 7, 2011),
http://www.genomeweb.com/mdx/dx-conference-fdas-gutierrez-sheds-further-light-plansrisk-based-ldt-regulation. See also FDA in Drafting Phasefor LDT Oversight, GENOMEWEB
DAILY NEWS (Oct. 5, 2010), http://www.genomeweb.com/Dxpgx/fda-drafting-phase-ldtoversight.
114. Over one hundred public presentations and comments regarding the regulation of
LDTs are available at Regulations.gov under Docket ID. FDA-20 10-N-0274.
115.

CTRS. FOR MEDICARE & MEDICAID SERVS. & U.S. FOOD & DRUG ADMIN., MOU

225-10-0010, MEMORANDUM OF UNDERSTANDING BETWEEN UNITED STATES FOOD AND
DRUG ADMINISTRATION AND CENTERS FOR MEDICARE & MEDICAID SERVICES (2010),

availableat http://www.fda.gov/aboutfda/partnershipscollaborations/Memorandaofunderstan
dingmous/domesticmous/ucm217585.htm.
116. Id.
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B. NIH Genetic Test Registry
In March 2010, the NIH announced the creation of the Genetic Testing
Registry (GTR), a public database that will provide increased access to
information about the availability, validity, and usefulness of genetic tests
1 7 The
to researchers, consumers, health care providers, and the public.H
GTR is intended to be a comprehensive resource that provides detailed
information about genetic tests currently available to patients."' Genetic
test companies will voluntarily provide the information included in the
GTR.119
The NIH published a detailed notice and request for comments about the
development of the GTR in June 2010.120 In addition to stressing that the
GTR will provide a centralized public resource with information about the
intended use, validity, and utility of genetic tests, the Federal Register
notice also indicated that the GTR will be used to facilitate the exchange of
Health Information Technology.12 1 Although the NIH clearly expressed
that certain information is expected to be incorporated in the GTR,
including information about the molecular basis and methods used for
testing, the NIH specifically requested comments regarding the types of
genetic tests and data elements that should be included in the GTR. 12 2 The
NIH also asked to receive comments about the potential uses, benefits, and
risks of the GTR. 123 In November 2010, the NIH held a public meeting to
discuss the development of the GTR.12 4 Although the GTR was expected to
be available for public use in 2011,125 the NIH has not yet issued any
specific statements regarding further development of the GTR.126
II. CHALLENGES FACING THE PROPOSED CHANGES
Although there are already three different pieces to the genetic testing
regulatory puzzle, two separate agencies in the DHHS have introduced

117. Press Release, Nat'l Insts. of Health, NIH Announces Genetic Testing Registry
(March 18, 2010), availableat http://www.nih.gov/news/health/mar201 0/od-I 8.htm.
118. Id
119. Id.
120. Request for Information (RFI) on the National Institutes of Health Plan to Develop
the Genetic Testing Registry, 75 Fed. Reg. 33,317 (June 11, 2010).
121. Id.
122. Id. at 33,318.
123. Id. at 33,318-19.
124. Plan to Develop a Genetic Testing Registry at the National Institutes of Health;
Public Meeting; Request for Comments, 75 Fed. Reg. 62,406 (Oct. 8, 2010).
125. Id. at 62,407.
126. The GTR is now expected to launch in early 2012. Genetic Testing Registry,
NAT'L CTR. FOR BIOTECHNOLOGY INFO., http://www.ncbi.nlm.nih.gov/gtr/ (last visited Oct.

23, 2011).
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proposals to address lingering concerns about genetic testing. 12 7 These
proposals are intended to fill in some of the holes that exist in the current
genetic testing regulatory framework. However, the FDA's decision to
revamp the regulation of LDTs, and the NIH's decision to create a GTR,
raise concerns about the implementation of these changes and the use of
agency and industry resources.
A. Revamped FDA Regulations
The public submissions responding to the FDA's notice for comments
and meeting highlighted a number of concerns regarding the development
and implementation of revamped LDT regulations. Many of the comments
stressed the need for clarity and consistency in the FDA regulation of LDTs
in order to ensure that consumers and researchers have access to clinically
valid and useful tests.12 8 Some of the laboratories and researchers raised
concerns that LDTs are currently used to respond to and diagnose emerging
health issues, and that overly burdensome regulations would limit the
availability of these tests in public health situations. 12 9
These comments stressed the need to ensure that any new regulatory
approach is flexible enough to accommodate rapid access to LDTs for rare
diseases or in public health emergencies.
The comments also expressed distinct views concerning the level of
regulation to which LDTs are currently subject. Some comments focused
on the fact that LDTs are already subject to regulation under CLIA and that
the reagents used in LDTs are already subject to FDA regulation. 13 0 Other
comments focused on the increasing complexity of LDTs and expressed
concern that certain tests enter the market without an adequate assessment
of analytical and clinical performance. 13 1 Underlying both sides of this
debate are concerns that new regulations will force manufacturers of LDTs
127. See supra Part I.A-B.
128. Tuma Ray, DTC Genomics Gets Time Before FDA as Agency Considers
Regulatory Strategy, PHARMACOGENOMICS REP. (July 21, 2010), http://www.genomeweb
.com/dxpgx/dtc-genomics-gets-time-fda-agency-considers-regulatory-strategy.
129. See, e.g., Letter from Patrick Luedtke, President, & Scott J. Becker, Exec. Dir.,
Ass'n of Pub. Health Labs., to Food & Drug Admin. (Aug. 4, 2010) (explaining that LDTs
are used when there is no equivalent FDA cleared test or when an outbreak occurs and the
community health leaders require timely disease confirmation).
130. See, e.g., American Society of Microbiology, Comments to FDA/CDRH at Public
Meeting on Oversight of Laboratory Developed Tests: Clinical Lab Challenges (July 20,
2010), http://www.asm.org/index.php/policy/ldtcomments7-20-10.html (discussing the ongoing validation of LDTs performance characteristics).
13 1. See, e.g., Letter from Justine Handelman, Exec. Dir., Office of Legislative and
Regulatory Policy, & Allan Korn, Senior Vice Presidet & Chief Med. Officer, Office of
Clinical Affairs, BlueCross BlueShield Ass'n, to Leslie Kux, Acting Assistant Comm'r for
Policy, Food & Drug Admin. (Aug. 2010) (stating that LDTs prepared without clinical
performance tests should be categorized as investigational rather than clinical tests).
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to meet divergent quality system requirements for the FDA and CLIA. The
duplication of verification and regulation would likely increase the costs of
these tests for consumers.13 2 However, as Dr. Shuren testified, the FDA and
CLIA regulations are supposed to complement one another; CLIA
regulations focus on the quality of the testing process, while FDA
regulations focus on the safety, effectiveness, quality, and manufacture of
diagnostic tests. 13 3 Since the FDA and CMS signed a MOU regarding this
issue in June 2010, it is likely that any new regulations for LDTs will
adequately balance the FDA and CLIA requirements.
One underlying problem is the concern that the FDA does not have an
adequate clearance pathway for genetic tests because the current clearance
pathway for medical devices is based on a demonstration of effectiveness
and safety. 134 The FDA has indicated that it intends to develop new LDT
regulations based on the level of risk each test presents, however, it is
difficult to determine how much risk a predictive genetic test presents. The
pre-market approval process does not really work for this kind of
technology because there is no definitive measure of "effectiveness."
Despite the debate about the necessary level of regulation the FDA
should have over LDTs, it makes sense for the FDA to exercise greater
regulation over these kinds of genetic tests. The initial distinctions drawn
between LDTs and genetic tests that include components that travel in
interstate commerce were tenuous at best. A large number of these tests are
now performed in laboratories separate from the developmental laboratories
and the patient care offices;135 the tests are no longer completed entirely in
one laboratory setting. In addition, in order to ensure that consumers and
researchers have access to accurate and valid tests, it makes more sense for
all tests to be subject to the same levels of regulation. However, there is
lingering concern because not all LDTs are genetic tests. The FDA's
decision to increase regulation of LDTs had already raised some questions
about the retail sale of other diagnostic tests to consumers. For example, in
November 2010, the FDA sent a letter to Identigene saying that the
company's home-use urine collection test for chlamydia and gonorrhea had
not been approved by the agency. 136 As some of the comments suggested, it
132. American Society of Microbiology, supra notel30.
133. Direct-to-Consumer Genetic Testing and the Consequences to the Public Health:
HearingBefore the Subcomm. on Oversight and Investigations of the H. Comm. on Energy
and Commerce, 110th Cong. 5 (2010) (statement of Dr. Jeffrey Shuren, Dir., Ctr. for
Devices and Radiological Health, U.S. Food & Drug Administration), available at
http://democrats.energycommerce.house.gov/documents
/20100722/Shuren.Testimony.07.22.20 10.pdf.
134. See 21 U.S.C. § 360c (2006) (indicating that the classification of medical devices
intended for human use is based on the safety and effectiveness of the particular device).
135. Oversight of Laboratory Developed Tests, 75 Fed. Reg. 34,463 (June 17, 2010).
136. Letter from James Woods, Deputy Dir., Patient Safety and Product Quality, Office
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may be necessary for the FDA to phase in any new regulations to ensure
continued patient access to LDTs currently being used."' Phased-in
regulations may also allow the FDA to develop the staffing and resources
necessary to implement these changes.m
B. NIH Registry Concerns
The NIH also received a large number of responses to its request for
information regarding the development of the GTR. 139 Although the
proposed GTR is voluntary, the initial recommendation of the Secretary's
Advisory Committee on Genetics, Health, and Society was to develop a
mandatory registry. 14 0 However, a number of genetic test companies stated
that they would discontinue their genetic test offerings if the GTR became
mandatory. 14 1 There is still some lingering uncertainty as to whether
genetic test companies will participate and provide meaningful or useful
information about their tests in a voluntary database. 142 The disclosure of
some information may be hampered by the NIH's expectation that the GTR
will be used to "[fjacilitate genetic and genomic data-sharing for research
and new scientific discoveries."1 4 3 Diagnostic firms and laboratories also
contend that posting clinical validity or utility information while that data is
still developing and emerging will not be a helpful measurement of the
tests' use.'" In addition, some test manufacturers have suggested keeping
of In Vitro Diagnostic Device Evaluations and Safety, Ctr. for Devices and Radiological
Health, to Steve Smith, Exec. Dir., IDENTIGENE (Nov. 4, 2010), available at
http://www.fda.gov/MedicalDevices/Productsand
MedicalProcedures/InVitroDiagnostics/ucm232746.htm See also Andrew Pollack, F.D.A.
Questions Drug Store Tests for Sexually Transmitted Diseases, N.Y. TIMES (Nov. 5, 2010,
8:41 PM), http://prescriptions.blogs.nytimes.com/2010/11/05/f-d-a-questions-drug-storetests-for-sexually-transmitted-diseases/.
137. See, e.g., Letter from Am. Soc'y for Clinical Pathology & The Joint Comm'n, to
Food & Drug Admin. (Aug. 13, 2010), availableat http://www.regulations.gov/#!document
Detail;D=FDA-2010-N-0274-0078 (outlining a process for applying a new regulatory
scheme to existing LDTs).
138. Kirell Lakhman, FDA's Effort to Update 'Consumers' on New ADx Developments
Are Not Up to Snuff THE SAMPLE (Nov. 19, 2010), http://www.genomeweb.com/blog/fdaseffort-update-consumers-new-mdx-developments-are-not-snuff.
139. See Request For Information Comments, OFFICE OF BIOTECH. ACTIVITIES.,
http://oba.od.nih.gov/GTR/gtrrfi comments.html (last visited October 25, 2011).
140.

SEC'Y'S ADVISORY COMM. ON GENETICS, HEALTH, AND Soc'Y, supra note 15, at

112-13.
141. Kirell Lakhman, Some AMP Members Would Discontinue Tests if NIH's Genetic
Test Registry Becomes Mandatory, THE SAMPLE (July 29, 2010), http://www.genomeweb
.com/blog/some-amp-members-would-discontinue-tests-if-nihs-genetic-test-registrybecomes-m.
142. Nat'l Inst. of Health, supra note 117.
143. Id.
144. Turna Ray, Comments on Genetic Testing Registry Highlight Wide Range of
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information about cost and reimbursement off the registry to avoid the
possibility that health insurance companies will use this information to

determine coverage.14 5
Another concern regarding the development of the GTR is that this
project seems to duplicate two already existent registries. The National
Center for Biotechnology Information (NCBI) already runs GeneTests, a
publicly funded medical information resource, 14 6 and GeneReviews, a
database of "expert-authored, peer-reviewed, current disease descriptions
that apply genetic testing to the diagnosis, management and genetic
counseling of patients and families with specific inherited conditions." 47
The NIH has indicated that GeneTests will continue to receive funding after
the GTR is developed, 14 8 and that GeneReviews will not be replaced. 14 9
Since the GTR will be developed by the NCBI,150 the same program that
already runs the GeneTests and GeneReviews databases, individuals in the
industry and working for the government have expressed concern that the
new NIH GTR will duplicate the two existing databases.' 5 During the
annual meeting of the Association for Molecular Pathology in November
2010, a highly respected lab director from the Weill Cornell Medical Center
in New York, specifically asked NIH officials why the GTR was being
created.152 In response to concerns about duplicative efforts, the Office of
Biotechnology Activity has explained that GeneTests was not built to
support the technologies that the GTR is intended to cover, so it makes
more sense technically and financially to develop a new database. 53
However, in order for the GTR to be a useful resource, the NIH needs to

Stakeholder Concerns,PHARMACOGENOMICS REP. (Oct. 20, 2010), http://www.genomeweb
.com/dxpgx/comments-genetic-testing-registry-highlight-wide-range-stakeholder-concems.
145.

Id.

146. GeneTests, NAT'L CTR. FOR BIOTECHNOLOGY INFO., http://www.ncbi.nim.nih.gov
/sites/GeneTests/?db=GeneTests(last visited Oct. 25, 2011).
147. GeneReviews, NAT'L CTR. FOR BIOTECHNOLOGY INFO.,http://www.ncbi.nlm.nih.gov
/projects/GeneTests/static/about/content/reviews.shtml (last visited Oct. 25, 2011).

148. Kirell Lakhman, Behind ACLA's 'Vapid,' 'Confusing,' 'Unhelpful,' and
'Ridiculous' LDT-IVD Meeting, THE SAMPLE (Dec. 6, 2010), http://www.genomeweb.com/
/node/957125?hq_e=el&hq m=889576&hq_1=7&hq_v-2a000b285a.
149. Matt Jones, NIH Meets Public on Genetic Test Registry, GENOMEWEB DAILY NEWS
(Nov. 3, 2010), http://www.genomeweb.com/dxpgx/nih-meets-public-genetic-test-registry.

150. Plan to Develop a Genetic Testing Registry at the National Institutes of Health, 75
Fed. Reg. 62,406, 62,407 (Oct. 8, 2010).
151. Lakhman, supra note 148.
152. Kirell Lakhman, Lab Director Sparks Controversy at AMP Conference by
Questioning 'Credibility' of NIH Genetic Testing Registry, THE SAMPLE (Nov. 20, 2010),
http://www.genomeweb.com/blog/lab-director-sparks-controversy-amp-conferencequestioning-credibility-nih-genet.
153. FrequentlyAsked Questions, OFFICE OF BIOTECHNOLOGY ACTIvrTy, http://oba.od
.nih.gov/GTR/gtr_faqs.html#GTR FAQ023 (last visited Dec. 15, 2010).
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avoid burdening the limited resources of laboratories with an additional
responsibility to update the same or similar information in multiple

places. 15 4
Perhaps the greatest concern raised regarding the development and
implementation of the GTR relates to practical concerns about how to best
organize the GTR so that the information is useful and can be easily
accessed and understood by all interested parties. Although some consumer
groups worry that the genetic test companies will not include enough useful
information in the registry, the corollary concern is that too much
information will be included in the registry, which will render it useless for
certain populations. Depending on what information is disclosed by the
genetic test companies, the information included in the registry may be too
technical for consumers, too simple for industry users, or too much for
anyone to sufficiently understand.
C. Another Mixed Message Regardingthe Genetic Testing Industry
An additional source of concern regarding the proposed changes to
genetic testing regulation is the recent decision by the Secretary of DHHS
to let the charter for the Secretary's Advisory Committee on Genetics,
Health, and Society (SACGHS) expire.155 The SACGHS was established in
2002 to:
(1) [p]rovide a forum for expert discussion and deliberation and the
formulation of advice and recommendations on the range of complex and
sensitive medical, ethical, legal and social issues raised by new
technological developments in human genetics; (2) assist the Department
of Health and Human Services and . .. other Federal agencies in

exploring issues raised by the development and application of genetic
technologies; and, (3) make recommendations to the Secretary of Health
and Human Services concerning how such issues should be addressed. 156
A scheduled review determined that the SACGHS had fulfilled its
mandate by successfully addressing the major topics related to genetic
technologies through comprehensive reports and recommendations. 157

154. Lakhman, supra note 141.
155. Turna Ray, HHS Will Not Renew SACGHS Charter,Ending Committee's DecadeLong Tenure in October, PHARMACOGENOMICS REP. (Sept. 29, 201 0),http://www.genomeweb
.com/dxpgx/hhs-will-not-renew-sacghs-charter-ending-committees-decade-long-tenureoctober.
156. Establishment of the Secretary's Advisory Committee on Genetics, Health, and
Society, 67 Fed. Reg. 65,126, 65,126 (Oct. 23, 2002).
157. Matt Jones, UPDATE: HHS to Let Secretary's Genetics Committee Expire,
GENOMEWEB DAILY NEWS (Sept. 28, 2010), http://www.genomeweb.com/hhs-let-secretarysgenetics-committee-expire.
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However, as evidenced by the recent FDA, Congressional, and NIH actions,
and as stated by an official from the NIH, "genetics-related issues are not
going away."158 Although other DHHS committees will assume some of
the SACGHS's duties, the number of recommendations set forth at the
SACGHS's last meeting, suggest that the Committee's work will not be
easily passed on.' 59
The termination of the SACGHS also sends a mixed message to the
industry and consumers regarding the status of genetic testing. The
SACGHS was first to suggest the development of a genetic test registry as a
way to provide more information about specific genetic tests and the
laboratories that perform them.160 The SACGHS was also first to suggest
that the FDA extend its regulatory oversight to all genetic tests.161 Now that
these recommendations are being considered and implemented, it seems
odd to dissolve the committee that first determined the need and basis for
change. Widespread, clinically-useful genetic testing still faces multiple
challenges and it is unclear whether the FDA, the NIH, and the DHHS are
fully prepared to respond to the competing interests and concerns that
remain.
IV. CONCLUSION
Genetic testing is currently regulated by three separate schemes and the
DHHS has proposed adding two significant pieces to the regulatory puzzle.
While there is certainly a need to complete the regulatory puzzle, the FDA
and NIH must ensure that any new pieces will help complete the picture
without stifling industry innovation.
One of the underlying problems with regulating genetic testing is that the
government, industry, clinicians, and consumers alike are still not sure how
this technology can best be used and what consequences will result from
using it. There is concern that the commercial viability of consumer
genetics is unproven,' 62 and neither of the current proposals address
concerns that individuals who receive genetic test results may not be able to
fully understand the results they receive.163 Although there is some debate
158. Id.
159. SACGHS Wraps Up with Recommendations on Sequencing, Comparative
Effectiveness, GENOMEWEB DAILY NEWS (Oct. 7, 2010), http://www.genomeweb.com/sacgh
s-wraps-recommendations-sequencing-comparative-effectiveness.
160. See SEC'Y's ADVISORY COMM. ON GENETICS, HEALTH, AND Soc'Y, supra note 15, at
112-13.
161. Id. at 112.
162. Hogarth, supra note 8, at 325.
163. See Guttmacher & Collins, supra note 1, at 997 (explaining that the "[p]roper
interpretation of screening results demands an understanding of the clinical implications of
specific genotypes.").
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about whether the concern that individuals will misunderstand their genetic
test results is exaggerated,164 these concerns are based on the notion that
genetic information is unique.
Previous legislation and regulations have reaffirmed that genetic
information is different than other medical information and therefore needs
special protection.165 Following this precedent, it makes sense to develop
specific regulations and policies that address the issues related to consumer
understanding of genetic test results. For example, the Center for Genetic
Research Ethics and Law, a recent venture developed through a partnership
between the Cleveland Clinic and Case Western Reserve University, is
trying to diffuse the misperceptions that many have about genetic testing
and research.16 6 Similarly, a requirement that a board-certified practitioner
complete the genetic test result interpretation would address concerns that
individuals do not receive enough sound medical information with their test
results. 16 7 Another possible solution would create a system where certain
high-risk genetic tests are only available through a physician and other tests
are available through the consumer market.168
Finally, Senator Orrin Hatch has suggested creating a new division
within the FDA, the Center for Advanced Diagnostics Evaluation and
Research, dedicated to the evaluation of diagnostic tests.16 9 This new
division would be responsible for ensuring the safety and efficacy of
"advanced personalized diagnostics," a new category of tests that includes
genetic tests and other LDTs.170 Senator Hatch's proposal defines an
164. Ciara Curtin, Researchers Report on Users' Understandingof Direct-to-Consumer
Genetic Test Results, GENOME TECH. (Nov. 30, 2010), http://www.genomeweb.com/dxpgx/
researchers-report-users-understanding-direct-consumer-genetic-test-results (explaining that
two recent studies found that early users of DTC genetic tests had a "moderately good
understanding of their risks."); cf Turna Ray, ASHG Studies Shed Light on Consumers'
Understandingof Gene Scan Reports, Response to Results, PHARMACOGENOMICS REP. (Nov.
10,
2010),
http://www.genomeweb.com/dxpgx/ashg-studies-shed-light-consumers
understanding-gene-scan-reports-response-resul (finding that DTC genetic test consumers
tended to feel that they understood more about their genetic test results than they actually
did).
165. See discussion of GINA infra Part I.C.
166. Center to Help Improve Patient Understanding of Genetic Testing, BIOETHICS
REFLECTIONS (Cleveland Clinic, Cleveland, Ohio), Fall 2010, at 6, available at
http://my.clevelandclinic.org/Documents/Bioethics/reflections/fall 10.pdf.
167. Genetics Experts Consider Tighter Regulation, Potential Ban on DTC Genetic
Testing, GENOMEWEB DAILY NEWS (Aug. 11, 2010), http://www.genomeweb.com/dxpgx/
genetics-experts-consider-tighter-regulation-potential-ban-dtc-genetic-testing.
168. Hogarth, supra note 8, at 324.
169. Turna Ray, Draft Bill Proposes FDA Create New Division to Review 'Advanced
PersonalizedDiagnostics',PHARMACOGENOMICS REP. (June 23, 2010), http://www.genome
web.com/dxpgx/draft-bill-proposes-fda-create-new-division-review-advanced-personalizeddiagnos.
170. Id.
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advanced personalized diagnostic as a medical product "distinct from a
device" and suggests "establish[ing] regulatory criteria that address the
unique characteristics of such products."' 7 ' Although Senator Hatch has not
yet introduced a bill with his proposal,172 this new legislation could
significantly impact any choices the FDA makes regarding the regulation of
LDTs.
Despite the flurry of activity, investigations, and comments collected
throughout 2010, the FDA, the NIH, and the DHHS are still trying to sort
out the pieces of the genetic testing regulatory puzzle. In the meantime,
DTC genetic testing companies continue to find new avenues into the
consumer marketplace. For example, in addition to expanded genetic
counseling offerings,17 3 23andMe recently announced a new annual
subscription-based plan that will enable the company to update its tests and
its customers' test results with an average of two to five new genetic
discoveries per month. 7 4 This is just one example of the wide range of
rapid changes that occur throughout the genetic testing industry, and
demonstrates why the DHHS needs to ensure that all pieces of the
regulatory puzzle are put into place without limiting industry innovation.
Better FDA regulation of LDTs and an organized, accessible, and useful
GTR may help create a complete picture of genetic test regulation.

171.

Turna Ray, Latest Draft of Hatch IVD Bill Contains New Regulatory Proposals;

Pricing Reforms

Under Discussion, PHARMACOGENOMICS

REP.

(July

6,

2011),

http://www.genomeweb.com/node/973340/?hqe=el_m=1046128_1=8_v-068ee2d6b0.
172. Id.
173.

23andMe Partnerto Provide Genetic Counseling, GENOMEWEB DAILY NEWS (June

7, 2010), http://www.genomeweb.com/dxpgx/23andme-partner-provide-genetic-counseling.
174. 23andMe Launches New Pricing Model, Charges Monthly Fee, GENOMEWEB
DAILY NEWS (Nov. 24, 2010), http://www.genomeweb.com/dxpgx/23andme-launches-newpricing-model-charges-monthly-fee.
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